Quanta Therapeutics

Quanta Therapeutics is pioneering allosteric modulation to directly restore conformational control of active RAS signaling at the cell membrane to inhibit the full scope of RAS-driven cancer types.

Quanta Therapeutics reports positive clinical trial results for its combination therapy targeting KRAS G12D-mutant colorectal cancer (CRC) at the European Society for Medical Oncology (ESMO) conference. The company also advances QTX6255, a pan-KRAS inhibitor, as part of its broader KRAS-focused pipeline development.

Oct 2026GlobeNewswire News RoomNews article

Quanta Therapeutics presents clinical trial data on **QTX3034** combined with **anti-EGFR therapy and chemotherapy** for treating **colorectal cancer (CRC)** at the **ESMO Congress**. The company also receives **FDA Fast Track designation** for QTX3034 in patients with **KRAS G12D mutations**, accelerating development for this hard-to-treat subgroup.

Oct 2026GlobeNewswireNews article

Quanta Therapeutics reports positive Phase 1 results for **QTX3034**, an oral KRAS inhibitor targeting the G12D mutation. The drug, tested alone and combined with cetuximab, shows a favorable safety profile and confirmed tumor responses in colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and endometrial cancer patients. Early data demonstrate clinical proof of concept for the multi-KRAS inhibitor approach in advanced solid tumors.

Oct 2025The Manila TimesNews article

Quanta Therapeutics presents Phase 1 clinical data for **QTX3034**, an oral **G12D-preferring multi-KRAS inhibitor**, at the **2025 AACR-NCI-EORTC conference** on molecular targets and cancer therapeutics. The company, a privately held biopharmaceutical firm, focuses on developing oral therapies for **RAS-driven cancers**. The presentation highlights early-stage findings for its investigational drug, which targets KRAS mutations linked to various cancers.

Oct 2025The Manila TimesNews article